The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NUVL | +4.8% | N/A | N/A | +405% |
| S&P | +12.57% | +87.93% | +13.44% | +52% |
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew Shair in January 2017 and is headquartered in Cambridge, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $6.24B | -12.7% |
| Market Cap / Employee | $43.91M | 0.0% |
| Employees | 142 | 54.3% |
| Net Income | -$122.44M | -45.2% |
| EBITDA | -$112.70M | -47.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $115.75M | -68.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -35.18% | -7.4% |
| Return On Invested Capital | -61.73% | -233.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$70.46M | -53.8% |
| Operating Free Cash Flow | -$70.46M | -53.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.95 | 4.73 | 5.42 | 6.63 | -36.24% |
| Price to Tangible Book Value | 4.95 | 4.73 | 5.42 | 6.63 | -36.24% |
| Enterprise Value to EBITDA | -51.59 | -42.24 | -42.80 | -46.99 | -35.38% |
| Return on Equity | -29.5% | -35.7% | -43.5% | -38.8% | 31.20% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
